Drug delivery strategies for improved azole antifungal action

Expert Opinion on Drug Delivery

Volumn 5, Issue 11, 2008, Pages 1199-1216

  Yang, Wei ^a   Wiederhold, Nathan P ^b   Williams III, Robert O ^a  

^a UNIVERSITY OF TEXAS AT AUSTIN   (United States)

^b UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

Author keywords

Azoles; Fungal infections; Intravenous; Oral; Pulmonary; Topical

Indexed keywords

BIFONAZOLE; BUTOCONAZOLE; CARBOMER; CARBOXYMETHYLCELLULOSE; CLOTRIMAZOLE; CREMOPHOR; ECONAZOLE; FENTICONAZOLE; FLUCONAZOLE; HYDROXYPROPYLCELLULOSE; ISOCONAZOLE; ITRACONAZOLE; KETOCONAZOLE; LIPOSOME; MACROGOL; MICONAZOLE; MICONAZOLE NITRATE; NIOSOME; OCTADECYLAMINE; OCTANOIN; OXICONAZOLE; POLOXAMER; POSACONAZOLE; PYRROLE DERIVATIVE; SOLID LIPID NANOPARTICLE; SULCONAZOLE; TERCONAZOLE; TIOCONAZOLE; UNINDEXED DRUG; VORICONAZOLE;

ANTIFUNGAL ACTIVITY; AREA UNDER THE CURVE; CREAM; DERMATOMYCOSIS; DIARRHEA; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG DELIVERY SYSTEM; DRUG DOSAGE FORM; DRUG DOSAGE FORM COMPARISON; DRUG EFFICACY; DRUG EXCRETION; DRUG FORMULATION; DRUG INTERMITTENT THERAPY; DRUG MEGADOSE; DRUG METABOLISM; DRUG PENETRATION; DRUG POTENCY; DRUG RESPONSE; DRUG RETENTION; DRUG SAFETY; DRUG SALIVA LEVEL; DRUG SOLUBILITY; DRUG STRUCTURE; DRUG TISSUE LEVEL; DRUG URINE LEVEL; ESOPHAGUS CANDIDIASIS; FOOD; FOOD DRUG INTERACTION; HUMAN; INVASIVE CANDIDIASIS; LIPOSOMAL DELIVERY; LOZENGE; LUNG ASPERGILLOSIS; MAXIMUM PLASMA CONCENTRATION; MICROEMULSION; MYCOSIS; NAUSEA; NAUSEA AND VOMITING; NONHUMAN; ONYCHOMYCOSIS; OROPHARYNX CANDIDIASIS; REVIEW; SINGLE DRUG DOSE; SUSTAINED DRUG RELEASE; TABLET; UNSPECIFIED SIDE EFFECT; VAGINA CANDIDIASIS; VOMITING;

ADMINISTRATION, ORAL; ADMINISTRATION, TOPICAL; ANIMALS; ANTIFUNGAL AGENTS; AZOLES; DRUG DELIVERY SYSTEMS; HUMANS; INJECTIONS, INTRAVENOUS;

EID: 57049163132     PISSN: 17425247     EISSN: None     Source Type: Journal    
DOI: 10.1517/17425240802457188     Document Type: Review

References (110)

1. Pfaller M, Wenzel R. The epidemiology of fungal infections. In: Elias EJ, McGinnis MR, Pfaller MA, editors, Clinical mycology. Elsevier Science: New York; 2003
2. Edmond MB, Wallace SE, McClish DK, et al. Nosocomial bloodstream infections in United States hospitals: a three-year analysis. Clin Infect Dis 1999;29(2):239-44
3. Pierard GE, Arrese JE, Quatresooz P, et al. Emerging therapeutic agents for onychomycosis. Expert Opin Emerging Drugs 2007;12(3):345-53
4. Chan OH, Stewart BH, Physicochemical and drug-delivery considerations for oral drug bioavailability. Drug Discov Today 1996;1(11):461-73
5. Canuto MM, Gutierrez F. Antifungal drug resistance to azoles and polyenes. Lancet Infect Dis 2002;2(9):550-63
6. Zonios DI, Bennett JE. Update on azole antifungals. Semin Resp Crit Care 2008;29(2):198-210
7. Fromtling RA. Overview of medically important antifungal azole derivatives. Clin Microbiol Rev 1988;1(2):187-217
8. Vanden Bossche H, Engelen M, Rochette F. Antifungal agents of use in animal health - chemical, biochemical and pharmacological aspects. J Vet Pharmacol Ther 2003;26(1):5-29
9. Rex JH, Bennett JE, Sugar AM, et al. A randomized trial comparing fluconazole with amphotericin B for the treatment of candidemia in patients without neutropenia. Candidemia Study Group and the National Institute. N Engl J Med 1994;331(20):1325-30
10. Pappas PG, Rex JH, Sobel JD, et al. Guidelines for treatment of candidiasis. Clin Infect Dis 2004;38(2):161-89
11. Debruyne D, Clinical pharmacokinetics ol fluconazole in superficial and systemic mycoses. Clin Pharmacokinet 1997;33(1):52-77
12. Humphrey MJ, Jevons S, Tarbit MH. Pharmacokinetic evaluation of UK-49,858, a metabolically stable triazole antifungal drug, in animals and humans. Antimicrob Agents Chemother 1985;28(5):648-53
13. Haneke E. Fluconazole levels in human epidermis and blister fluid. Br J Dermatol 1990;123(2):273-4
14. De Beule K, Van Gestel J. Pharmacology of itraconazole. Drugs 2001;61:27-37
15. Cauwenbergh G, Degreef H, Heykants J, et al. Pharmacokinetic profile of orally-administered itraconazole in human-skin. J Am Acad Dermatol 1988;18(2):263-8
16. Hitchcock C, Pye G, Oliver G, et al. UK-109,496, a novel, wide-spectrum triazole derivative for the treatment of fungal infections: antifungal activity and selectivity in vitro. In: 35th Interscience Conference on Antimicrobial Agents and Chemotherapy; 1995; Washington
17. VFEND Pi, Package insert. VFEND Tablets/VFEND IV. (voriconazole). 2002, New York: Pfizer Roerig
18. Page RL, Schwiesow J, Hilts A. Posaconazole as salvage therapy in a patient with disseminated zygomycosis: case report and review of the literature. Pharmacotherapy 2007;27(2):290-8
19. Raad I, Chapman S, Bradsher R, et al. Posaconazole (POS) salvage therapy for invasive fungal infections (IFI). In: Forty-fourth Interscience Conference on Antimicrobial Agents and Chemotherapy; 2004; Washington, DC
20. Ullmann AJ, Cornely OA, Burchardt A, et al. Pharmacokinetics, safety, and efficacy of posaconazole in patients with persistent febrile neutropenia or refractory invasive fungal infection. Antimicrob Agents Chemother 2006;50(2):658-66
21. Torres HA, Hachem RY, Chemaly RF, et al. Posaconazole: a broad-spectrum triazole antifungal. Lancet Infect Dis 2005;5(12):775-85
22. Sansone-Parsons A, Krishna G, Calzetta A, et al. Effect of a nutritional supplement on posaconazole pharmacokinetics following oral administration to healthy volunteers. Antimicrob Agents Chemother 2006;50(5):1881-3
23. Degreef HJ, Dedoncker PRG. Current therapy of dermatophytosis. J Am Acad Dermatol 1994;31(3):S25-30
24. Ghosh TK, Pfister WR, Yum SI. Transdermal and topical drug delivery systems. Buffalo Grove, IL: Interpharm Press; 1997
25. Alberti I, Kalia YN, Naik A, et al. Effect of ethanol and isopropyl myristate on the availability of topical terbinafine in human stratum corneum, in vivo. Int J Pharm 2001;219(1-2):11-9
26. Kemken J, Ziegler A, Muller BW. Influence of supersaturation on the pharmacodynamic effect of bupranolol after dermal administration using microemulsions as vehicle. Pharm Res 1992;9(4):554-8
27. Hadgraft J. Passive enhancement strategies in topical and transdermal drug delivery. Int J Pharm 1999;184(1):1-6
28. Kondo S, Yamasaki-Konishi H, Sugimoto I. Enhancement of transdermal delivery by superfluous thermodynamic potential. II. In vitro-in vivo correlation of percutaneous nifedipine transport. J Pharmacobio Dynamics 1987;10(11):662-8
29. El Laithy HM, El-Shaboury KM. The development of Cutina lipogels and gel microemulsion for topical administration of fluconazole. AAPS PharmSciTech 2002;3(4):E35
30. Rojanasakul Y, Wang LY, Bhat M, et al. The transport barrier of epithelia - a comparative study on membrane-permeability and charge selectivity in the rabbit. Pharm Res 1992;9(8):1029-34
31. Piemi MPY, Korner D, Benita S, et al. Positively and negatively charged submicron emulsions for enhanced topical delivery of antifungal drugs. J Control Release 1999;58(2):177-87
32. Kim MK, Chung SJ, Lee MH, et al. Targeted and sustained delivery of hydrocortisone to normal and stratum corneum-removed skin without enhanced skin absorption using a liposome gel. J Control Release 1997;46(3):243-51
33. Yoshioka T, Sternberg B, Florence AT. Preparation and properties of vesicles (Niosomes) of sorbitan monoesters (Span-20, Span-40, Span-60 and Span-80) and a Sorbitan Triester (Span-85). Int J Pharm 1994;105(1):1-6
34. Fang JY, Hong CT, Chiu WT, et al. Effect of liposomes and niosomes on skin permeation of enoxacin. Int J Pharm 2001;219(1-2):61-72
35. Ning MY, Guo YZ, Pan HZ, et al. Preparation, in vitro and in vivo evaluation of liposomal/niosomal gel delivery systems for clotrimazole. Drug Dev Ind Pharm 2005;31(4-5):375-83
36. Muller RH, Ruhl D, Runge S, et al. Cytotoxicity of solid lipid nanoparticles as a function of the lipid matrix and the surfactant. Pharm Res 1997;14(4):458-62
37. Muller RH, Mader K, Gohla S. Solid lipid nanoparticles (SLN) for controlled drug delivery - a review of the state of the art. Eur J Pharm Biopharm 2000;50(1):161-77
38. Wissing SA, Lippacher A, Muller RH. Investigations on the occlusive properties of solid lipid nanoparticles (SLN). J Cosmet Sci 2001;52(5):313-24
39. Souto EB, Wissing SA, Barbosa CM, et al. Development of a controlled release formulation based on SLN and NLC for topical clotrimazole delivery. Int J Pharm 2004;278(1):71-7
40. Souto EB, Muller RH. The use of SLN and NLC as topical particulate carriers for imidazole antifungal agents. Pharmazie 2006;61(5):431-7
41. Sanna V, Gavini E, Cossu M, et al. Solid lipid nanoparticles (SLN) as carriers for the topical delivery of econazole nitrate: in vitro characterization, ex vivo and in vivo studies. J Pharm Pharmacol 2007;59(8):1057-64
42. Bouckaert S, Schautteet H, Lefebvre RA, et al. Comparison of salivary miconazole concentrations after administration of a bioadhesive slow-release buccal tablet and an oral gel. Eur J Clin Pharmacol 1992;43(2):137-40
43. Codd JE, Deasy PB. Formulation development and in vivo evaluation of a novel bioadhesive lozenge containing a synergistic combination of antifungal agents. Int J Pharm 1998;173(1-2):13-24
44. Karasulu HY, Hilmioglu S, Metin DY, et al. Efficacy of a new ketoconazole bioadhesive vaginal tablet on Candida albicans. Farmaco 2004;59(2):163-7
45. Wang L, Tang X. A novel ketoconazole bioadhesive effervescent tablet for vaginal delivery: design, in vitro and 'in vivo' evaluation. Int J Pharm 2008;350(1-2):181-7
46. Francois M, Snoeckx E, Putteman P, et al. A mucoadhesive, cyclodextrin-based vaginal cream formulation of itraconazole. AAPS Pharmsci 2003;5(1):E5
47. Furneri PM, Corsello S, Masellis G, et al. Econazole-polycarbophil, a new delivery system for topical therapy: microbiological and clinical results on vaginal candidiasis. J Chemother 2008;20(3):336-40
48. Mididoddi PK, Repka MA. Characterization of hot-melt extruded drug delivery systems for onychomycosis. Eur J Pharm Biopharm 2007;66(1):95-105
49. Trey SM, Wicks DA, Mididoddi PK, et al. Delivery of itraconazole from extruded HPC films. Drug Dev Ind Pharm 2007;33(7):727-35
50. Hui XY, Chan TCK, Barbadillo S, et al. Enhanced econazole penetration into human nail by 2-n-nonyl-1,3-dioxolane. J Pharm Sci 2003;92(1):142-8
51. Baran R, Coquard F. Combination of fluconazole and urea in a nail lacquer for treating onychomycosis. J Dermatol Treat 2005;16(1):52-5
52. Loftsson T, Brewster ME. Pharmaceutical applications of cyclodextrins.1. Drug solubilization and stabilization. J Pharm Sci 1996;85(10):1017-25
53. Brewster ME, Vandecruys R, Verreck G, et al. Supersaturating drug delivery systems: effect of hydrophilic cyclodextrins and other excipients on the formation and stabilization of supersaturated drug solutions. Pharmazie 2008;63(3):217-20
54. Hostetler JS, Hanson LH, Stevens DA. Effect of cyclodextrin on the pharmacology of antifungal oral azoles. Antimicrob Agents Chemother 1992;36(2):477-80
55. Pedersen M. Isolation and antimycotic effect of a genuine miconazole beta-cyclodextrin complex. Eur J Pharm Biopharm 1994;40(1):19-23
56. Tenjarla S, Puranajoti P, Kasina R, et al. Preparation, characterization, and evaluation of miconazole-cyclodextrin complexes for improved oral and topical delivery. J pharm Sci 1998;87(4):425-9
57. Taneri F, Guneri T, Aigner Z, et al. Improvement of the physicochemical properties of clotrimazole by cyclodextrin complexation. J Incl Phenom Macro 2003;46(1-2):1-13
58. Taneri F, Guneri T, Aigner Z, et al. Improvement in the physicochemical properties of ketoconazole through complexation with cyclodextrin derivatives. J Incl Phenom Macro 2002;44(1-4):257-60
59. Taneri F, Guneri T, Aigner Z, et al. Influence of cyclodextrin complexation on the physicochemical and biopharmaceutical properties of ketoconazole. J Incl Phenom Macro 2003;47(1-2):15-23
60. Yong CS, Li DX, Prabagar B, et al. The effect of beta-cyclodextrin complexation on the bioavailability and hepatotoxicity of clotrimazole. Pharmazie 2007;62(10):756-9
61. Pedersen M, Bjerregaard S, Jacobsen J, et al. A genuine clotrimazole gamma-cyclodextrin inclusion complex-isolation, antimycotic activity, toxicity and an unusual dissolution rate. Int J Pharm 1998;176(1):121-31
62. Peeters J, Neeskens P, Tollenaere JP, et al. Characterization of the interaction of 2-hydroxypropyl-beta-cyclodextrin with itraconazole at pH 2, 4, and 7. J Pharm Sci 2002;91(6):1414-22
63. Poirier JM, Cheymol G. Optimisation of itraconazole therapy using target drug concentrations. Clin Pharmacokinet 1998;35(6):461-73
64. Barone JA, Koh JG, Bierman RH, et al. Food interaction and steady-state pharmacokinetics of itraconazole capsules in healthy male-volunteers. Antimicrob Agents Chemother 1993;37(4):778-84
65. Sporanox® pl, Package insert. Sporanox capsules/oral solution/ Sporanox I.V. (itraconazole)
66. Willems L, van der Geest R, de Beule K. Itraconazole oral solution and intravenous formulations: a review of pharmacokinetics and pharmacodynamics. J Clin Pharm Ther 2001;26(3):159-69
67. Gould S, Scott RC. 2-hydroxypropyl-beta-cyclodextrin (HP-beta-CD): a toxicology review. Food Chem Toxicol 2005;43(10):1451-9
68. Stella VJ, He Q. Cyclodextrins. Toxicol Pathol 2008;36(1):30-42
69. VandeVelde VJS, VanPeer AP, Heykants JJP, et al. Effect of food on the pharmacokinetics of a new hydroxypropyl-beta-cyclodextrin formulation of itraconazole. Pharmacotherapy 1996;16(3):424-8
70. Buchanan CM, Buchanan NL, Edgar KJ, et al. Pharmacokinetics of itraconazole after intravenous and oral dosing of itraconazole-cyclodextrin formulations. J Pharm Sci 2007;96(11):3100-16
71. Gursoy RN, Benita S. Self-emulsifying drug delivery systems (SEDDS) for improved oral delivery of lipophilic drugs. Biomed Pharmacother 2004;58(3):173-82
72. Hong JY, Kim JK, Song YK, et al. A new self-emulsifying formulation of itraconazole with improved dissolution and oral absorption. J Control Release 2006;110(2):332-8
73. Woo JS, Song YK, Hong JY, et al. Reduced food-effect and enhanced bioavailability of a self-microemulsifying formulation of itraconazole in healthy volunteers. Eur J Pharm Sci 2008;33(2):159-65
74. FDA, Guidance for Industry - Nonclinical Studies for the Safety evaluation of Pharmaceutical Excipients. F.a.D. Administration, Editor, 2005
75. Park MJ, Ren S, Lee BJ. In vitro and in vivo comparative study of itiraconazole bioavailability when formulated in highly soluble self-emulsifying system and in solid dispersion. Biopharm Drug Dispos 2007;28(4):199-207
76. Jaiswal J, Gupta SK, Kreuter J. Preparation of biodegradable cyclosporine nanoparticles by high-pressure emulsification-solvent evaporation process. J Control Release 2004;96(1):169-78
77. Pandey R, Ahmad Z, Sharma S, et al. Nano-encapsulation of azole antifungals: Potential applications to improve oral drug delivery. Int J Pharm 2005;301(1-2):268-76
78. Peng HS, Liu XJ, Lv GX, et al. Voriconazole into PLGA nanoparticles: Improving agglomeration and antifungal efficacy. Int J Pharm 2008;352(1-2):29-35
79. Leuner C, Dressman J. Improving drug solubility for oral delivery using solid dispersions. Eur J Pharm Biopharm 2000;50(1):47-60
80. Kapsi SG, Ayres JW. Processing factors in development of solid solution formulation of itraconazole for enhancement of drug dissolution and bioavailability. Int J Pharm 2001;229(1-2):193-203
81. Janssens S, Nagels S, de Armas HN, et al. Formulation and characterization of ternary solid dispersions made up of Itraconazole and two excipients, TPGS 1000 and PVPVA 64, that were selected based on a supersaturation screening study. Eur J Pharm Biopharm 2008;69(1):158-66
82. Six K, Daems T, de Hoon J, et al. Clinical study of solid dispersions of itraconazole prepared by hot-stage extrusion. Eur J Pharm Sci 2005;24(2-3):179-86
83. Kwon K, Kim ST, Ahn CH, et al. The efficacy and safety of short-term therapy with itraconazole melt-extrusion tablet in the hyperkeratotic type of Tinea pedis and/or Tinea manus. Korean J Med Mycol 2000;5(1):13-9
84. Moon K, Koh JK, Cho BK, et al. Efficacy of itraconazole melt-extrusion tablet one-week therapy in treatment of hyperkeratotic type of Tinea pedis and/or Tinea manus. Korean J Dermatol 1999;37(8):1047-56
85. Miller DA, McConville JT, Yang W et al. Hot-melt extrusion for enhanced delivery of drug particles. J Pharm Sci 2007;96(2):361-76
86. Miller DA, DiNunzio JC, Yang W, et al. Targeted intestinal delivery of supersaturated itraconazole for improved oral absorption. Pharm Res 2008;25(6):1450-59
87. Leconte P, Joly V, Saintjulien L, et al. Tissue distribution and antifungal effect of liposomal itraconazole in experimental cryptococcosis and pulmonary aspergillosis. Am Rev Respir Dis 1992;145(2):424-9
88. OrthoBiotech. Available from: http://www.fda.gov/Cder/Drug/shortages/ Sporanox-10-11-2007.pdf 2007 [cited].
89. Kipp JE. Using NANOEDGE in the rapid development of water-insoluble drug formulations. In: The Seventh Annual Drug Delivery Partnerships Conference/Institute for International Research (IIR); 2003; San Diego
90. Rabinow B, Kipp J, Papadopoulos P, et al. Itraconazole IV nanosuspension enhances efficacy through altered pharmacokinetics in the rat. Int J Pharm 2007;339(1-2):251-60
91. Merisko-Liversidge E, Liversidge GG, Cooper ER. Nanosizing: a formulation approach for poorly water-soluble compounds. Eur J Pharm Sci 2003;18(2):113-20
92. Mouton JW, van Peer A, de Beule K, et al. Pharmacokinetics of itraconazole and hydroxyitraconazole in healthy subjects after single and multiple doses of a novel formulation. Antimicrob Agents Chemother 2006;50(12):4096-102
93. Muller RH, Schmidt S, Bottle I, et al. SolEmuls (R) - novel technology for the formulation of i.v. emulsions with poorly soluble drugs. Int J Pharm 2004;269(2):293-302
94. Akkar A, Muller RH. Intravenous itraconazole emulsions produced by SolEmuls technology. Eur J Pharm Biopharm 2003;56(1):29-36
95. Barratt G. Colloidal drug carriers: achievements and perspectives. Cell Mol Life Sci 2003;60(1):21-37
96. de Assis DN, Mosqueira VCF, Vilela JMC, et al. Release profiles and morphological characterization by atomic force microscopy and photon correlation spectroscopy of (99m) Technetium-fluconazole nanocapsules. Int J Pharm 2008;349(1-2):152-60
97. Marr KA, Carter RA, Crippa F, et al. Epidemiology and outcome of mould infections in hematopoietic stem cell transplant recipients. Clin Infect Dis 2002;34(7):909-17
98. Elder EJ, Hitt JE, Rogers TL, et al. Particle engineering of poorly water soluble drugs by controlled precipitation. Acs Sym Ser 2006;924:292-304
99. Vaughn JM, Gao X, Yacaman MJ, et al. Comparison of powder produced by evaporative precipitation into aqueous solution (EPAS) and spray freezing into liquid (SFL) technologies using novel Z-contrast STEM and complimentary techniques. Eur J Pharm Biopharm 2005;60(1):81-9
100. Overhoff KA, Engstrom JD, Chen B, et al. Novel ultra-rapid freezing particle engineering process for enhancement of dissolution rates of poorly water-soluble drugs. Eur J Pharm Biopharm 2007;65(1):57-67
101. Edwards DA, Ben-Jebria A, Langer R. Recent advances in pulmonary drug delivery using large, porous inhaled particles. J Appl Physiol 1998;85(2):379-85
102. McConville JT, Overhoff KA, Sinswat P, et al. Targeted high lung concentrations of itraconazole using nebulized dispersions in a murine model. Pharm Res 2006;23(5):901-11
103. McConville JT, Williams RO, Carvalho TC, et al. Design and evaluation of a restraint-free small animal inhalation dosing chamber. Drug Dev Ind Pharm 2005;31(1):35-42
104. Sobel JD. Practice guidelines for the treatment of fungal infections. For the Mycoses Study Group. Infectious Diseases Society of America. Clin Infect Dis 2000;30(4:652
105. Hoeben BJ, Burgess DS, McConville JT, et al. In vivo efficacy of aerosolized nanostructured itraconazole formulations for prevention of invasive pulmonary aspergillosis. Antimicrob Agents Chemother 2006;50(4):1552-4
106. Alvarez CA, Wiederhold NP, McConville JT, et al. Aerosolized nanostructured itraconazole as prophylaxis against invasive pulmonary aspergillosis. J Infect 2007;55(1):68-74
107. McConville JT, Wiederhold NP. Invasive pulmonary aspergillosis: therapeutic and prophylactic strategies. In: Williams RO 3rd, Taft DR, McConville JT, editors, Advanced drug formulation design to optimize therapeutic outcomes. Informa Healthcare: New York, NY; 2007. p. 53-80
108. Yang W, Tam J, Miller DA, et al. High bioavailability from nebulized intraconazole nanoparticle dispersions with biocompatible stabilizers. Int J Pharm 2008;361(1-2):177-88
109. Liu FY, Shao Z, Kildsig DO, et al. Pulmonary delivery of free and liposomal insulin. Pharm Res 1993;10(2):228-32
110. Yang W, Peters JI, Williams RO 3rd. Inhaled nanoparticles - a current review. Int J Pharm 2008;356(1-2):239-47